Crossmark

Early administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study

Crossref DOI link: https://doi.org/10.1007/s40618-025-02542-3

Published Online: 2025-01-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Piasentier, Alberto

Fanti, Alessandro

Birtolo, Maria Francesca

Vena, Walter

Colle, Roberto

Gentile, Lucrezia Maria Silvana

Jaafar, Simona

Bossi, Antonio Carlo

Lania, Andrea G.

Mazziotti, Gherardo
License Information

Text and Data Mining valid from 2025-01-31

Version of Record valid from 2025-01-31
More Information

Article History

Received: 6 November 2024

Accepted: 24 January 2025

First Online: 31 January 2025

Declarations

:

: The Authors declare the following competing financial interests: Andrea G. Lania received grants from Pfizer and consultancy fees from Ipsen, outside the submitted work; Gherardo Mazziotti received consultancy fees from Sanofi and UCB and lecture fees from Amgen, Theramex and Abiogen, outside the submitted work; moreover, Gherardo Mazziotti serves as Associate Editor for Journal of Endocrinological Investigation. Walter Vena is a member of the editorial board of Journal of Endocrinological Investigation. The other authors have nothing to declare.

: The study was approved by the Ethics Committee of IRCCS Humanitas Research Hospital.

: The study was conducted in accordance with the Declaration of Helsinki, and all participants gave their written informed consent.

Document is current

Any future updates will be listed below